Fig. 1: Establishment and validation of 18 cell death pattern models and CCDI models. | npj Precision Oncology

Fig. 1: Establishment and validation of 18 cell death pattern models and CCDI models.

From: Integrating bulk, single-cell, and spatial transcriptomics to identify and functionally validate novel targets to enhance immunotherapy in NSCLC

Fig. 1: Establishment and validation of 18 cell death pattern models and CCDI models.The alternative text for this image may have been generated using AI.

a The graphic abstract of the study. b Area under the curve (AUC) values of time-dependent ROC curves for 1- to 5-year survival predictions of 18 PCD models are shown, with each point representing the AUC and vertical lines indicating the 95% confidence interval (CI). c ROC curves for autophagic cell death (ACD), necroptosis, and combined cell death index (CCDI) models for overall survival (OS). d Time-dependent ROC curves for the CCDI model at 1, 2, 3, 4, and 5 years. e Kaplan–Meier curves for high-risk and low-risk patient subgroups classified by risk scores of ACD, necroptosis, and CCDI models. Dashed lines represent the 95% CI of survival curves. (The high-risk and low-risk groups were distinguished by the minimum p-value method; log-rank test, P < 0.0001). f Assessment of the ability of ACD, necroptosis, and CCDI models discriminating between low-risk and high-risk groups with Uniform Manifold Approximation and Projection (UMAP). PCD programmed cell death, DSP digital spatial profiling, ICI immune checkpoint inhibitor, ICD immunogenic cell death, LCD lysosome-dependent cell death, SC single-cell, ST spatial transcriptomic, ROI regions of interest, AIS adenocarcinoma in situ, MIA minimally invasive adenocarcinoma, IAC invasive adenocarcinoma, NMPR non-major pathological response, MPR major pathological response, T tumor in situ, M metastatic tumor, LDH lactate dehydrogenase, Co-IP co-immunoprecipitation. *P < 0.05, **P < 0.01, ***P < 0.001.

Back to article page